Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bicara Therapeutics Inc.BCAX · Entity 4673 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bicara Therapeutics Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.56 · Expires 2036-06-09 | Direct | 19,475 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 19,475 · Balance 19,475 F1: The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DICE Therapeutics, Inc.
Report date August 09, 2023 · Filed August 09, 2023
Section 16 reporting ended · disclosed 2023-08-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 1
1 source rowRow 1 · 2023-08-09 · Disposition to issuer · Disposed 198,000 · Balance 0 F1: On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the "Issuer" or the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the "Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased for $48.00 per share (the "Offer Price"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-09 · Disposition to issuer · Disposed 7,191 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company's Stock Option (the "Option") is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-09 · Disposition to issuer · Disposed 771 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company's Stock Option (the "Option") is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-09 · Disposition to issuer · Disposed 20,751 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company's Stock Option (the "Option") is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-09 · Disposition to issuer · Disposed 2,688 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company's Stock Option (the "Option") is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-08-09 · Disposition to issuer · Disposed 9,095 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5: The Option vests as to 1/48th of the total shares monthly, beginning August 27, 2020, subject to the Reporting Holder's continuing employment with the Registrant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-08-09 · Disposition to issuer · Disposed 16,595 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Option vests as to 1/48th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continuing employment with the Registrant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-08-09 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F7: The Option vests as to 1/48th of the total shares monthly, beginning August 2, 2021, subject to the Reporting Holder's continuing employment with the Registrant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-08-09 · Disposition to issuer · Disposed 56,920 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F8: The Option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continuing employment with the Registrant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.64 · Expires 2032-04-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-08-09 · Disposition to issuer · Disposed 154,250 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F9: The Option vests as to 1/48th of the total shares monthly, beginning January 1, 2022, until such time as the option is 100% vested on the four-year anniversary, subject to the Reporting Holder's continued service to the Registrant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.31 · Expires 2033-01-26 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-08-09 · Disposition to issuer · Disposed 112,500 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F10: The Option vests as to 1/48th of the total shares monthly, beginning January 27, 2023, until such time as the option is 100% vested on the four-year anniversary, subject to the Reporting Holder's continued service to the Registrant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-08-09 · Disposition to issuer · Disposed 18,750 · Balance 0 F11: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement for no consideration. F13: Pursuant to the Merger Agreement, each RSU that was outstanding but not vested as of immediately prior to the Closing (the "Unvested RSU"), became immediately vested in full (the "Vested RSU"). Each Vested RSU was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the Offer Price by (ii) the number of shares of Common Stock underlying such RSU. F12: The RSUs vest as to 1/4th of the total shares annually, beginning January 27, 2023, until such time as the RSUs are 100% vested on the four-year anniversary, subject to the Reporting Holder's continued service to the Registrant. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the "Issuer" or the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the "Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased for $48.00 per share (the "Offer Price"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested.
F3: The Company's Stock Option (the "Option") is fully vested and exercisable.
F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.
F5: The Option vests as to 1/48th of the total shares monthly, beginning August 27, 2020, subject to the Reporting Holder's continuing employment with the Registrant.
F6: The Option vests as to 1/48th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continuing employment with the Registrant.
F7: The Option vests as to 1/48th of the total shares monthly, beginning August 2, 2021, subject to the Reporting Holder's continuing employment with the Registrant.
F8: The Option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continuing employment with the Registrant.
F9: The Option vests as to 1/48th of the total shares monthly, beginning January 1, 2022, until such time as the option is 100% vested on the four-year anniversary, subject to the Reporting Holder's continued service to the Registrant.
F10: The Option vests as to 1/48th of the total shares monthly, beginning January 27, 2023, until such time as the option is 100% vested on the four-year anniversary, subject to the Reporting Holder's continued service to the Registrant.
F11: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement for no consideration.
F12: The RSUs vest as to 1/4th of the total shares annually, beginning January 27, 2023, until such time as the RSUs are 100% vested on the four-year anniversary, subject to the Reporting Holder's continued service to the Registrant.
F13: Pursuant to the Merger Agreement, each RSU that was outstanding but not vested as of immediately prior to the Closing (the "Unvested RSU"), became immediately vested in full (the "Vested RSU"). Each Vested RSU was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the Offer Price by (ii) the number of shares of Common Stock underlying such RSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 10, 2026 20:33 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | GrantStock Option (Right to Buy) · Derivative | 19,475 | $0.00 Strike: $20.56 | $0.00 |
DisclosureSEC source: 0001628280-26-042249 · wk-form4_1781123614.xml · derivative · entry 1 Robertson Scott M. · CIK 0001882035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,475 Underlying: Common Stock · 19,475 shares Expires 2036-06-09 F1 · derivative.exercise_date: The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:28 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | GrantStock Option (Right to Buy) · Derivative | 23,746 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0002023658-25-000075 · wk-form4_1749587311.xml · derivative · entry 1 Robertson Scott M. · CIK 0001882035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,746 Underlying: Common Stock · 23,746 shares Expires 2035-06-09 F1 · derivative.exercise_date: This option was awarded to the reporting person pursuant to the Issuer's 2024 Stock Option and Incentive Plan. The shares underlying this option shall vest upon the earlier of (i) June 9, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| September 12, 2024 Filed Sep 16, 2024 20:35 UTC | Bicara Therapeutics Inc. BCAX · Entity 4673 | GrantStock Option (Right to Buy) · Derivative | 23,746 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0000950170-24-106868 · ownership.xml · derivative · entry 1 Robertson Scott M. · CIK 0001882035 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,746 Underlying: Common Stock · 23,746 shares Expires 2034-09-12 F1 · derivative.exercise_date: The shares underlying this option shall vest upon the earlier of (i) August 16, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:31 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerRestricted Stock Units · Derivative | 18,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045180 · doc4.xml · derivative · entry 12 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,750 shares Expires not disclosed F11 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement for no consideration. F13 · price: Pursuant to the Merger Agreement, each RSU that was outstanding but not vested as of immediately prior to the Closing (the "Unvested RSU"), became immediately vested in full (the "Vested RSU"). Each Vested RSU was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the Offer Price by (ii) the number of shares of Common Stock underlying such RSU. F12 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually, beginning January 27, 2023, until such time as the RSUs are 100% vested on the four-year anniversary, subject to the Reporting Holder's continued service to the Registrant. F12 · derivative.expiration_date: The RSUs vest as to 1/4th of the total shares annually, beginning January 27, 2023, until such time as the RSUs are 100% vested on the four-year anniversary, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:31 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 112,500 | Not disclosed Strike: $32.31 | Not disclosed |
DisclosureSEC source: 0001209191-23-045180 · doc4.xml · derivative · entry 11 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 112,500 shares Expires 2033-01-26 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F10 · derivative.exercise_date: The Option vests as to 1/48th of the total shares monthly, beginning January 27, 2023, until such time as the option is 100% vested on the four-year anniversary, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:31 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 154,250 | Not disclosed Strike: $19.64 | Not disclosed |
DisclosureSEC source: 0001209191-23-045180 · doc4.xml · derivative · entry 10 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 154,250 shares Expires 2032-04-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F9 · derivative.exercise_date: The Option vests as to 1/48th of the total shares monthly, beginning January 1, 2022, until such time as the option is 100% vested on the four-year anniversary, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:31 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 56,920 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045180 · doc4.xml · derivative · entry 9 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,920 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F8 · derivative.exercise_date: The Option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:31 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045180 · doc4.xml · derivative · entry 8 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F7 · derivative.exercise_date: The Option vests as to 1/48th of the total shares monthly, beginning August 2, 2021, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:31 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 16,595 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045180 · doc4.xml · derivative · entry 7 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,595 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6 · derivative.exercise_date: The Option vests as to 1/48th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:31 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 9,095 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045180 · doc4.xml · derivative · entry 6 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,095 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5 · derivative.exercise_date: The Option vests as to 1/48th of the total shares monthly, beginning August 27, 2020, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:31 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 2,688 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045180 · doc4.xml · derivative · entry 5 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,688 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company's Stock Option (the "Option") is fully vested and exercisable. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:31 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 20,751 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045180 · doc4.xml · derivative · entry 4 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,751 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company's Stock Option (the "Option") is fully vested and exercisable. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:31 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 771 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045180 · doc4.xml · derivative · entry 3 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 771 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company's Stock Option (the "Option") is fully vested and exercisable. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:31 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 7,191 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045180 · doc4.xml · derivative · entry 2 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,191 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company's Stock Option (the "Option") is fully vested and exercisable. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:31 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerCommon Stock | 198,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045180 · doc4.xml · nonDerivative · entry 1 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the "Issuer" or the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the "Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · price: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased for $48.00 per share (the "Offer Price"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested. Read SEC document |
| May 03, 2023 Filed May 5, 2023 21:19 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | SaleCommon Stock | 18,750 | $36.55 | $685,350.00 |
DisclosureSEC source: 0001209191-23-027790 · doc4.xml · nonDerivative · entry 1 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,000 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 28, 2022. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.50 to $36.63 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:44 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantRestricted Stock Unit (RSU) · Derivative | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005778 · doc4.xml · derivative · entry 2 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually, beginning January 27, 2023, until such time as the RSUs are 100% vested on the four-year anniversary, subject to the Reporting Holder's continued service to the Registrant. F3 · derivative.expiration_date: The RSUs vest as to 1/4th of the total shares annually, beginning January 27, 2023, until such time as the RSUs are 100% vested on the four-year anniversary, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 22:44 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 112,500 | $0.00 Strike: $32.31 | $0.00 |
DisclosureSEC source: 0001209191-23-005778 · doc4.xml · derivative · entry 1 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2033-01-26 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning January 27, 2023, until such time as the option is 100% vested on the four-year anniversary, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| April 14, 2022 Filed Apr 19, 2022 23:05 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 154,250 | $0.00 Strike: $19.64 | $0.00 |
DisclosureSEC source: 0001209191-22-024837 · doc4.xml · derivative · entry 1 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,250 Underlying: Common Stock · 154,250 shares Expires 2032-04-14 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning January 1, 2022, until such time as the option is 100% vested on the four-year anniversary, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:21 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056521 · doc4.xml · derivative · entry 15 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2031-09-14 F9 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:21 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056521 · doc4.xml · derivative · entry 14 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2031-09-14 F9 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:21 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056521 · doc4.xml · derivative · entry 13 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-09-14 F9 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:21 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056521 · doc4.xml · derivative · entry 12 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2031-09-14 F9 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:21 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056521 · doc4.xml · derivative · entry 11 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-09-14 F9 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:21 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 920 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056521 · doc4.xml · derivative · entry 10 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920 Underlying: Common Stock · 920 shares Expires 2031-09-14 F9 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:21 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 9,750 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056521 · doc4.xml · derivative · entry 9 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,750 Underlying: Common Stock · 9,750 shares Expires 2031-09-14 F9 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:21 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056521 · doc4.xml · derivative · entry 8 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-09-14 F8 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning August 2, 2021, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:21 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 16,595 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056521 · doc4.xml · derivative · entry 7 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,595 Underlying: Common Stock · 16,595 shares Expires 2031-09-14 F7 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:21 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 9,095 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056521 · doc4.xml · derivative · entry 6 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,095 Underlying: Common Stock · 9,095 shares Expires 2031-09-14 F6 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning August 27, 2020, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:21 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 2,688 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056521 · doc4.xml · derivative · entry 5 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,688 Underlying: Common Stock · 2,688 shares Expires 2031-09-14 F5 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning February 28, 2019, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:21 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 20,751 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056521 · doc4.xml · derivative · entry 4 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,751 Underlying: Common Stock · 20,751 shares Expires 2031-09-14 F4 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning December 1, 2017, subject to the Reporting Holder's continuing employment with the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:21 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 771 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056521 · doc4.xml · derivative · entry 3 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771 Underlying: Common Stock · 771 shares Expires 2031-09-14 F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:21 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 7,191 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056521 · doc4.xml · derivative · entry 2 Robertson Scott M. · CIK 0001882035 · CFO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,191 Underlying: Common Stock · 7,191 shares Expires 2031-09-14 F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.